NASDAQ:CDXC ChromaDex (CDXC) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free CDXC Stock Alerts $3.39 +0.44 (+14.92%) (As of 02:46 PM ET) Add Compare Share Share Today's Range$2.94▼$3.4450-Day Range$1.52▼$4.3252-Week Range$1.25▼$4.65Volume365,081 shsAverage Volume263,472 shsMarket Capitalization$255.30 millionP/E RatioN/ADividend YieldN/APrice Target$5.87 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ChromaDex alerts: Email Address ChromaDex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside81.1% Upside$5.87 Price TargetShort InterestBearish2.95% of Float Sold ShortDividend StrengthN/ASustainability-1.62Upright™ Environmental ScoreNews Sentiment0.57Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.02) to $0.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.72 out of 5 starsMedical Sector272nd out of 910 stocksMedicinals & Botanicals Industry2nd out of 11 stocks 3.5 Analyst's Opinion Consensus RatingChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChromaDex has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.95% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in ChromaDex has recently increased by 12.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldChromaDex does not currently pay a dividend.Dividend GrowthChromaDex does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChromaDex has received a 58.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Dietary supplements" products. See details.Environmental SustainabilityThe Environmental Impact score for ChromaDex is -1.62. Previous Next 2.5 News and Social Media Coverage News SentimentChromaDex has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ChromaDex this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for CDXC on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added ChromaDex to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChromaDex insiders have not sold or bought any company stock.Percentage Held by Insiders10.57% of the stock of ChromaDex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.41% of the stock of ChromaDex is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ChromaDex are expected to grow in the coming year, from ($0.02) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChromaDex is -46.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChromaDex is -46.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChromaDex has a P/B Ratio of 8.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About ChromaDex Stock (NASDAQ:CDXC)ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Read More CDXC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXC Stock News HeadlinesApril 23, 2024 | businesswire.comChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketApril 23, 2024 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Stock Crosses Above 200 Day Moving Average of $1.88April 23, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 17, 2024 | msn.comChromaDex (CDXC) Price Target Increased by 9.92% to 6.60March 27, 2024 | stocknews.com3 Chemical Stocks Poised for GainsMarch 26, 2024 | businesswire.comChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramMarch 8, 2024 | finance.yahoo.comChromaDex Full Year 2023 Earnings: EPS Beats ExpectationsMarch 8, 2024 | uk.sports.yahoo.comPersona 3 Reload is getting the DLC it needs, but not the one it deservesApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 7, 2024 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDAMarch 6, 2024 | markets.businessinsider.comWhat Wall Street expects from ChromaDex's earningsMarch 6, 2024 | investorplace.comCDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023March 6, 2024 | benzinga.comEarnings Preview For ChromaDexMarch 6, 2024 | finance.yahoo.comChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 ResultsMarch 2, 2024 | finance.yahoo.comInsiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the companyFebruary 21, 2024 | finance.yahoo.comChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024February 21, 2024 | businesswire.comChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024February 6, 2024 | entrepreneur.comTop 3 Accelerating Chemical Stocks to ConsiderFebruary 5, 2024 | finance.yahoo.comChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024January 26, 2024 | finance.yahoo.comChromaDex to Present at the Lytham Partners 2024 Investor Select ConferenceJanuary 24, 2024 | seekingalpha.comChromaDex: Growth At A Reasonable PriceJanuary 19, 2024 | finance.yahoo.comChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To ProfitDecember 20, 2023 | businesswire.comChromaDex Supports the US Military with its Industry Leading NAD + Supplement, Tru NiagenDecember 20, 2023 | baystreet.caChromaDex Flat on Assistance to MilitaryDecember 20, 2023 | finance.yahoo.comChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®November 30, 2023 | finance.yahoo.comA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)See More Headlines Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2023Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:CDXC CUSIPN/A CIK1386570 Webwww.chromadex.com Phone(310) 388-6706Fax949-419-0294Employees106Year FoundedN/APrice Target and Rating Average Stock Price Target$5.87 High Stock Price Target$6.60 Low Stock Price Target$5.00 Potential Upside/Downside+98.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,940,000.00 Net Margins-5.91% Pretax Margin-5.91% Return on Equity-17.81% Return on Assets-9.17% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio1.70 Sales & Book Value Annual Sales$83.57 million Price / Sales2.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book7.76Miscellaneous Outstanding Shares75,310,000Free Float67,349,000Market Cap$222.16 million OptionableOptionable Beta1.98 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Frank Louis Jaksch Jr. (Age 56)Co-Founder & Chairman Comp: $292.27kMr. Robert N. Fried (Age 64)CEO & Director Comp: $735.54kMs. Brianna Gerber (Age 43)Chief Financial Officer Comp: $509.82kDr. Andrew Shao Ph.D.Senior Vice President of Global Regulatory & Scientific AffairsHeather Van BlarcomSenior VP of Legal & Corporate SecretaryAlex WorshamVice President of Global Marketing & CommunicationsMr. David KroesSenior Vice President of People MattersMs. Chu YanManaging Director of Asia PacificMr. Jason CampbellSenior Vice President of Business DevelopmentKendall KnyschHead of Media Relations & PartnershipsMore ExecutivesKey CompetitorsAurora CannabisNASDAQ:ACBMenlo TherapeuticsNASDAQ:FOMXMediWoundNASDAQ:MDWDbioteNASDAQ:BTMDFitLife BrandsNASDAQ:FTLFView All CompetitorsInsiders & InstitutionsTieton Capital Management LLCBought 461,692 shares on 2/9/2024Ownership: 3.879%International Assets Investment Management LLCBought 8,600 shares on 1/24/2024Ownership: 0.038%Brianna GerberBought 5,000 shares on 12/1/2023Total: $7,050.00 ($1.41/share)Frank L Jaksch JrBought 7,000 shares on 6/12/2023Total: $11,830.00 ($1.69/share)Robert N FriedBought 7,000 shares on 5/31/2023Total: $9,940.00 ($1.42/share)View All Insider TransactionsView All Institutional Transactions CDXC Stock Analysis - Frequently Asked Questions Should I buy or sell ChromaDex stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDXC shares. View CDXC analyst ratings or view top-rated stocks. What is ChromaDex's stock price target for 2024? 2 analysts have issued twelve-month price targets for ChromaDex's shares. Their CDXC share price targets range from $5.00 to $6.60. On average, they anticipate the company's stock price to reach $5.87 in the next year. This suggests a possible upside of 81.1% from the stock's current price. View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts. How have CDXC shares performed in 2024? ChromaDex's stock was trading at $1.43 at the start of the year. Since then, CDXC shares have increased by 126.6% and is now trading at $3.24. View the best growth stocks for 2024 here. Are investors shorting ChromaDex? ChromaDex saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,320,000 shares, an increase of 12.8% from the March 15th total of 1,170,000 shares. Based on an average daily volume of 259,700 shares, the days-to-cover ratio is presently 5.1 days. Currently, 3.0% of the company's stock are short sold. View ChromaDex's Short Interest. When is ChromaDex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CDXC earnings forecast. How were ChromaDex's earnings last quarter? ChromaDex Co. (NASDAQ:CDXC) announced its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm earned $21 million during the quarter, compared to the consensus estimate of $21.08 million. ChromaDex had a negative net margin of 5.91% and a negative trailing twelve-month return on equity of 17.81%. During the same period in the prior year, the company posted ($0.08) EPS. What is Robert Fried's approval rating as ChromaDex's CEO? 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend. What other stocks do shareholders of ChromaDex own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL). How do I buy shares of ChromaDex? Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDXC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
